Last reviewed · How we verify
NCT05823636
The Clinical Course and Factors for the Progression of Uninvestigated Dyspepsia to Functional Dyspepsia
trial in Dyspepsia in 220 participants. Currently enrolling.
30 June 2025
Quick facts
| Lead sponsor | Air Force Military Medical University, China |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 220 |
| Start date | 1 January 2023 |
| Primary completion | 30 June 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Dyspepsia — all drugs for Dyspepsia →
Sponsor
Air Force Military Medical University, China
Who can join
18 and older, any sex, with Dyspepsia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dyspepsia is one of the most common gastrointestinal diseases. This disease was defined as predominant epigastric pain lasting for at least 1 month, which can be accompanied with other symptoms, such as epigastric fullness, and early satiety. Despite dyspepsia symptoms lasting for ≥1 month represented clinical problem, a longer duration of 6 months or more after first-onset symptom was required for the diagnosis of functional dyspepsia based on ROME IV criteria. It was unclear about the natural procession of first-onset dyspepsia to functional dyspepsia assessed by Rome IV or Asia criteria and possible factors associated with this progression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05823636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dyspepsia
Currently open trials in the same condition.
- NCT06941545 — High Resolution Gastric Mapping and Gastroduodenal Manometry · NA · recruiting
- NCT07261228 — The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper · recruiting
- NCT06755671 — A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms · recruiting
- NCT06422052 — Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspep · recruiting
- NCT05810168 — Traditional Dietary Advice Versus Low FODMAP Diet in Postprandial Functional Dyspepsia · NA · recruiting
Other Air Force Military Medical University, China trials
Trials by the same sponsor.
- NCT07535138 — Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy · EARLY_PHASE1 · not yet recruiting
- NCT07454408 — Evaluation of the Outcome of Fecal Microbiota Transplantation · Phase 1, PHASE2 · not yet recruiting
- NCT07329660 — Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients · NA · not yet recruiting
- NCT07365345 — Frequency of Electrical Acupoint Stimulation on Hypotension in TAVR Patients · NA · recruiting
- NCT07338448 — Electrical Acupoint Stimulation on Gastric Reflux During I-gel Ventilation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05823636 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Air Force Military Medical University, China
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05823636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing